Skip to main content
. 2023 Sep 13;6(9):e2329583. doi: 10.1001/jamanetworkopen.2023.29583

Figure 2. Two-Way Deterministic Sensitivity Analysis of Pharmaceutical Cost and Retention for Extended-Release Buprenorphine Cost-Effectiveness Plot.

Figure 2.

This figure represents the cost-effective strategy at a $100 000 per quality-adjusted life years (QALY) willingness-to-pay threshold when we vary both retention and cost for extended-release buprenorphine at the same time in increments of 5%. The values in the upper right side of the figure, where the dots turn to darkest, are combinations of retention increases and cost reductions resulting in the treatment with extended-release buprenorphine strategy no longer being dominated.